Why Medical Evaluation Should Be a Part of ADHD Assessment
December 29, 2023
Not all patients presenting with attentional/cognitive deficits and...
Read More
ADHD Medications and Long-Term Risk of Cardiovascular Diseases: New Data
December 4, 2023
This recently published case-control study explores the potential c...
Read More
A Potential New Non-Stimulant Treatment Option For ADHD
November 27, 2023
Encouraging outcomes from two Phase 3 clinical trials assessing the...
Read More
Highlights from 2023 NEI Congress: Sessions on ADHD
November 11, 2023
Attention deficit hyperactivity disorder (ADHD) is a common neurode...
Read More
ADHD as a Risk Factor For Being Involved in Intimate Partner Violence
October 12, 2023
In this systematic review and meta-analysis of 14 studies including...
Read More
FDA Approves Multiple Generics of ADHD and BED Treatment
August 28, 2023
The U.S. Food and Drug Administration has approved several first g...
Read More
Childhood Adversity and the Cortisol Awakening Response in Depression
August 3, 2023
The hypothalamic pituitary adrenal (HPA) axis is the main regulator...
Read More
Stimulant Treatment in Youth Not Associated With Substance Use Later in Life
July 16, 2023
Childhood attention-deficit/hyperactivity disorder (ADHD) is linked...
Read More
Long-Term Safety of Methylphenidate in Children and Adolescents with ADHD
April 29, 2023
Methylphenidate (MPH) is the most frequently prescribed treatment f...
Read More
Risk of Cardiovascular Diseases Associated With Medications Used in ADHD
December 19, 2022
In a recent cohort study, the relationship benzodiazepines versus a...
Read More
ADHD Polygenic Risk Scores Impact On Outcomes
October 25, 2022
Early identification of ADHD is critical when it comes to mitigatin...
Read More
Adult ADHD Linked To Elevated Risk Of Cardiovascular Diseases
October 10, 2022
The cardiovascular safety of attention-deficit/hyperactivity disord...
Read More